Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Insulet to Spotlight New Data and Innovations Demonstrating How Omnipod® Simplifies Diabetes Management and Delivers Strong Clinical Outcomes at the American Diabetes Association 86th Scientific Sessions

Presentations will feature next generation Omnipod innovations designed to reduce user effort, new algorithm data, and clinical evidence demonstrating improved time in range

Insulet-led sessions will highlight how patient-centered design and strong clinical performance is helping redefine Automated Insulin Delivery (AID) across type 1 and type 2 diabetes

Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its planned activities during the American Diabetes Association (ADA) 86th Scientific Sessions, taking place June 5 – 8, 2026 in New Orleans.

“At Insulet, we believe diabetes technology should do more and demand less from the people who rely on it every day,” said Ashley McEvoy, President and CEO of Insulet. “The data and innovations we’re sharing at ADA reflect this commitment, showing how Omnipod is advancing AID by improving outcomes, reducing disease burden, and unlocking barriers to AID adoption.”